Search
Now showing items 1-3 of 3
Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling
(Research Policy, 2020-09-12)
We provide causal evidence that regulation induced product shocks significantly impact aggregate demand and firm performance in pharmaceutical markets. Event study results suggest an average loss between $569 million and ...
Generic competition and the incentives for early-stage pharmaceutical innovation
(Elsevier, 2022-12-01)
What impact has rising generic competition had on the nature and direction of pharmaceutical innovation? We find broad-based, strong evidence that pharmaceutical companies have diverted their new drug development efforts ...
Research and market structure: evidence from an antibiotic-resistant pathogenic outbreak
(Elsevier, 2023-01)
We provide causal evidence that upstream research shocks impact unconnected downstream product markets. Focusing on the Indian pharmaceutical market, we use a natural experiment involving a publication that identified a ...